CA3002544C - 5-ht2c receptor agonists and compositions and methods of use - Google Patents

5-ht2c receptor agonists and compositions and methods of use Download PDF

Info

Publication number
CA3002544C
CA3002544C CA3002544A CA3002544A CA3002544C CA 3002544 C CA3002544 C CA 3002544C CA 3002544 A CA3002544 A CA 3002544A CA 3002544 A CA3002544 A CA 3002544A CA 3002544 C CA3002544 C CA 3002544C
Authority
CA
Canada
Prior art keywords
individual
compound
pharmaceutically acceptable
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3002544A
Other languages
English (en)
French (fr)
Other versions
CA3002544A1 (en
Inventor
Albert S. Ren
Graeme Semple
Xiuwen Zhu
Carleton R. Sage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CA3002544A1 publication Critical patent/CA3002544A1/en
Application granted granted Critical
Publication of CA3002544C publication Critical patent/CA3002544C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3002544A 2015-04-27 2016-04-26 5-ht2c receptor agonists and compositions and methods of use Active CA3002544C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153082P 2015-04-27 2015-04-27
US62/153,082 2015-04-27
PCT/US2016/029308 WO2016176177A1 (en) 2015-04-27 2016-04-26 5-ht2c receptor agonists and compositions and methods of use

Publications (2)

Publication Number Publication Date
CA3002544A1 CA3002544A1 (en) 2016-11-03
CA3002544C true CA3002544C (en) 2024-03-05

Family

ID=55949111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3002544A Active CA3002544C (en) 2015-04-27 2016-04-26 5-ht2c receptor agonists and compositions and methods of use

Country Status (18)

Country Link
US (1) US10392390B2 (enExample)
EP (1) EP3288946B1 (enExample)
JP (1) JP6675688B2 (enExample)
KR (1) KR102275505B1 (enExample)
CN (1) CN107873030B (enExample)
AU (1) AU2016255009B2 (enExample)
BR (1) BR112017023088B1 (enExample)
CA (1) CA3002544C (enExample)
DK (1) DK3288946T3 (enExample)
EA (1) EA034446B1 (enExample)
ES (1) ES2757922T3 (enExample)
HK (1) HK1244005B (enExample)
HR (1) HRP20192044T1 (enExample)
HU (1) HUE047169T2 (enExample)
IL (1) IL255171A0 (enExample)
MX (2) MX373319B (enExample)
PT (1) PT3288946T (enExample)
WO (1) WO2016176177A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN111670050A (zh) 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
ES3049086T3 (en) * 2019-02-08 2025-12-12 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
US12205686B2 (en) * 2020-02-27 2025-01-21 The Cleveland Clinic Foundation Identifying patients for intensive hyperglycemia management
WO2023076533A1 (en) * 2021-10-29 2023-05-04 Sensorium Therapeutics, Inc. Solid forms of mesembrine and therapeutic uses thereof
WO2023108164A2 (en) * 2021-12-10 2023-06-15 GATC Health Corp Methods of treating ptsd and neurological disorders
KR20240158959A (ko) 2022-03-10 2024-11-05 아레나 파마슈티칼스, 인크. 치료 방법
CN114965250B (zh) * 2022-05-19 2025-02-14 道生天合材料科技(上海)股份有限公司 胶粘剂储存期的预测方法
WO2023225773A1 (en) * 2022-05-23 2023-11-30 Sensorium Therapeutics, Inc. Solid forms of mesembrine and therapeutic uses thereof
WO2024118987A1 (en) 2022-12-02 2024-06-06 Arena Pharmaceuticals, Inc. Methods of treatment
US20260116851A1 (en) * 2023-02-17 2026-04-30 Caamtech, Inc. 2-(2,5-diethoxy-4-(ethylthio)phenyl)ethane-1-aminium chloride
JP2026508371A (ja) * 2023-03-02 2026-03-10 アレクサンダー シュルギン リサーチ インスティチュート、インコーポレイテッド フェニルアルキルアミンのプロドラッグ
TW202529748A (zh) * 2023-10-11 2025-08-01 義大利帕多瓦大學 使用賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）及賽洛辛（ｐｓｉｌｏｃｉｎ）衍生物之治療方法
WO2026025075A1 (en) 2024-07-26 2026-01-29 Arena Pharmaceuticals, Inc. Bexicaserin for use in the treatment and/or prevention of epileptic disorders in a child patient
WO2026043678A1 (en) 2024-08-23 2026-02-26 Arena Pharmaceuticals, Inc. Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy
WO2026075995A1 (en) 2024-10-01 2026-04-09 Arena Pharmaceuticals, Inc. Hydrochloric acid salt of a 5-ht2c agonist
WO2026103793A1 (zh) * 2024-11-13 2026-05-21 上海翰森生物医药科技有限公司 三稠环类化合物、其制备方法和应用
WO2026107229A1 (en) * 2024-11-15 2026-05-21 The Board Of Trustees Of The Leland Stanford Junior University Reducing the addictive liability of opioid analgesics by co- administering 5ht2 receptor agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642822A (en) * 1969-11-03 1972-02-15 Upjohn Co Hexahydropyrrolobenzodiazepines
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4920989A (en) 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
WO2002036596A2 (en) * 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
DE60106641T2 (de) * 2000-11-03 2005-12-01 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
CN1805938B (zh) * 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
MX2008012093A (es) * 2006-03-24 2008-10-03 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
EP2824106B1 (en) * 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Tricyclic compound
BR112015005743A2 (pt) * 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use

Also Published As

Publication number Publication date
WO2016176177A1 (en) 2016-11-03
MX2020005898A (es) 2020-08-13
MX2017013902A (es) 2018-03-16
EP3288946A1 (en) 2018-03-07
HK1244005B (en) 2020-04-17
US10392390B2 (en) 2019-08-27
AU2016255009A1 (en) 2017-12-14
EA034446B1 (ru) 2020-02-10
PT3288946T (pt) 2019-11-27
DK3288946T3 (da) 2019-11-25
HRP20192044T1 (hr) 2020-02-07
AU2016255009B2 (en) 2020-10-08
KR20170140317A (ko) 2017-12-20
BR112017023088B1 (pt) 2023-10-03
CA3002544A1 (en) 2016-11-03
EA201792356A1 (ru) 2018-05-31
CN107873030B (zh) 2021-03-19
KR102275505B1 (ko) 2021-07-08
ES2757922T3 (es) 2020-04-30
IL255171A0 (en) 2017-12-31
CN107873030A (zh) 2018-04-03
NZ737412A (en) 2021-06-25
US20180186797A1 (en) 2018-07-05
HUE047169T2 (hu) 2020-04-28
JP2018519251A (ja) 2018-07-19
EP3288946B1 (en) 2019-08-21
MX373319B (es) 2020-06-13
JP6675688B2 (ja) 2020-04-01
BR112017023088A2 (pt) 2018-07-10

Similar Documents

Publication Publication Date Title
AU2016255009B2 (en) 5-HT2C receptor agonists and compositions and methods of use
HK1244005A1 (en) 5-ht2c receptor agonists and compositions and methods of use
US11395824B2 (en) 5-HT2C receptor agonists and compositions and methods of use
US11608339B2 (en) 5-HT2C receptor agonists and compositions and methods of use
WO2015066344A1 (en) 5-ht2c receptor agonists and compositions and methods of use
JP2018519251A5 (enExample)
US20170096398A1 (en) Non-hygroscopic salts of 5-ht2c agonists
NZ737412B2 (en) 5-ht2c receptor agonists and compositions and methods of use
NZ739883B2 (en) 5-ht2c receptor agonists and compositions and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210419

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401